LYEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LYEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Lyell Immunopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Lyell Immunopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $55.16 Mil. Lyell Immunopharma's annualized EBITDA for the quarter that ended in Mar. 2024 was $-202.20 Mil. Lyell Immunopharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.27.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Lyell Immunopharma's Debt-to-EBITDA or its related term are showing as below:
During the past 5 years, the highest Debt-to-EBITDA Ratio of Lyell Immunopharma was -0.25. The lowest was -0.40. And the median was -0.28.
The historical data trend for Lyell Immunopharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Debt-to-EBITDA | -0.27 | -0.26 | -0.34 | -0.40 | -0.28 |
Lyell Immunopharma Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.27 | -0.25 | -0.27 | -0.29 | -0.27 |
For the Biotechnology subindustry, Lyell Immunopharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Lyell Immunopharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (6.273 | + | 56.894) | / | -226.758 | |
= | -0.28 |
Lyell Immunopharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0 | + | 55.159) | / | -202.204 | |
= | -0.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
Lyell Immunopharma (NAS:LYEL) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Lyell Immunopharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Klausner | director, officer: Executive Chairman | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Matthew Lang | officer: Chief Business Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Rahsaan Thompson | officer: Chief Legal Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Tina M. Albertson | officer: Chief Medical Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Gary K. Lee | officer: Chief Scientific Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Cathy Friedman | director | C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
Arch Venture Fund Ix Overage, L.p. | 10 percent owner | 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
Elizabeth Homans | director, officer: Chief Executive Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Stephen J. Hill | officer: Chief Technical Ops. Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Charles W. Newton | officer: Chief Financial Officer | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Otis W Brawley | director | 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518 |
Elizabeth G Nabel | director | BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Arch Venture Partners Ix, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Ix, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By sperokesalga sperokesalga • 06-07-2023
By Value_Insider Value_Insider • 11-02-2022
By Marketwired • 07-05-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Value_Insider Value_Insider • 11-07-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By sperokesalga sperokesalga • 05-04-2023
By Value_Insider Value_Insider • 11-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.